Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of “Moderate Buy” from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $38.33.

DNLI has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $35.00 target price on shares of Denali Therapeutics in a research report on Monday, September 9th. Wedbush cut their price objective on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. JPMorgan Chase & Co. raised their price objective on shares of Denali Therapeutics from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Denali Therapeutics in a research report on Wednesday, September 4th. Finally, Bank of America raised their price target on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $22.12, for a total value of $663,600.00. Following the completion of the sale, the director now directly owns 34,404 shares in the company, valued at $761,016.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. CWM LLC lifted its position in Denali Therapeutics by 216.7% in the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after acquiring an additional 1,376 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Denali Therapeutics by 27.0% in the fourth quarter. Victory Capital Management Inc. now owns 15,348 shares of the company’s stock valued at $329,000 after purchasing an additional 3,267 shares in the last quarter. Fisher Asset Management LLC bought a new stake in shares of Denali Therapeutics in the fourth quarter valued at about $59,000. Charles Schwab Investment Management Inc. boosted its position in shares of Denali Therapeutics by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,006,997 shares of the company’s stock worth $21,610,000 after buying an additional 25,938 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Denali Therapeutics by 17.7% during the fourth quarter. BNP Paribas Financial Markets now owns 191,643 shares of the company’s stock worth $4,113,000 after buying an additional 28,817 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

DNLI stock opened at $30.77 on Friday. The company has a 50 day moving average price of $23.68 and a 200 day moving average price of $21.05. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $31.00. The stock has a market capitalization of $4.41 billion, a PE ratio of -32.05 and a beta of 1.37.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.09. The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $10.00 million. During the same quarter in the previous year, the firm earned $1.30 EPS. The company’s revenue was down 99.7% compared to the same quarter last year. As a group, equities analysts expect that Denali Therapeutics will post -2.54 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.